IDDI Reports Successful Partnership with Tigenix for Approval of Chondrocelect

Successful Partnership with Tigenix for Approval of Chondrocelect for Cartilage Repair

IDDI’s contributed statistical methodology towards approval of ChondroCelect® TiGenix’s lead product for the treatment of cartilage repair in the knee.

Louvain-la-Neuve, August 27, 2009 – IDDI (International Drug Development Institute), a corporation based in Belgium, reports that its collaboration with TiGenix resulted in the approval by European Medicines Agency for the Evaluation of Medicinal Products (EMEA) of ChondroCelect® for the treatment of full thickness cartilage defects in the knee. On June 26, 2009, ChondroCelect® was the first cell therapy product to receive a positive opinion from the Committee for Advanced Therapies (CAT) and the Committee for Medicinal Products for Human Use (CHMP) on the European Marketing Authorisation application (MAA) under the new regulation on advanced-therapy medicinal products.


Fill this form to access to our link

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information